Effect of administration of moxifloxacin plus rifampin against mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system

mBio

Volumn 2, Issue 4, 2011, Pages

  Drusano, G L ^a   Sgambati, N ^a,b   Eichas, A ^a   Brown, D ^a   Kulawy, R ^a   Louie, A ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; RIFAMPICIN; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; BACTERIAL COUNT; DRUG EFFECT; GENETIC SELECTION; HUMAN; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MUTATION; TIME;

MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; AZA COMPOUNDS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; RIFAMPIN; SELECTION, GENETIC; TIME FACTORS;

EID: 84858754002     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00108-11     Document Type: Article

References (8)

1. Dorman SE, et al. 2009. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 180:273-280.
2. Conde MB, et al. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189.
3. Weiner M, et al. 2007. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob. Agents Chemother. 51:2861-2866.
4. O'Sullivan DM, Hinds J, Butcher PD, Gillespie SH, McHugh TD. 2008. Mycobacterium tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacin. J. Antimicrob. Chemother. 62:1199-1202.
5. Weiner M, et al. 2004. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am. J. Respir. Crit. Care Med. 169:1191-1197.
6. Drusano GL, et al. 2010. The combination of rifampin plus moxifloxacin is synergistic for resistance suppression, but is antagonistic for cell kill for Mycobacterium tuberculosis as determined in a hollow fiber infection model. mBio 1:e00139-10.
7. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130.
8. D'Argenio DZ, Schumitzky A. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA http://bmsr.usc.edu/.